COPENHAGEN (Reuters) -Danish drugmaker Novo Nordisk will invest 15. "This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide," Novo's head of product supply, quality and IT, Henrik Wulff, said in a statement. Novo, which produces API at two facilities in Denmark and one in Clayton, North Carolina, in the United States, said last year it planned to invest 5